XML 38 R9.htm IDEA: XBRL DOCUMENT v2.4.1.9
Liquidity
12 Months Ended
Dec. 31, 2014
Accounting Policies [Abstract]  
Liquidity
2. Liquidity:

At December 31, 2014, the Company had cash and cash equivalents of approximately $70.5 million. The Company used $28.8 million of cash from operations during the twelve months ended December 31, 2014 and had stockholders’ equity of $54.4 million, versus deficit of ($0.8) million at December 31, 2013. The Company has sufficient cash to manage the business into early 2016, although this assumes that the Company does not accelerate the development of other opportunities available to the Company, engage in an extraordinary transaction or otherwise face unexpected events, costs or contingencies, any of which could affect the Company’s cash requirements.

Additional capital may be required to support planned development of Clonidine Topical Gel, Buprenorphine Depot Injection, the Company’s commercialization activities for BUNAVAIL®, the reformulation project for and anticipated commercial relaunch of ONSOLIS® and general working capital. Based on product development timelines and agreements with the Company’s development partners, the ability to scale up or reduce personnel and associated costs are factors considered throughout the product development life cycle. Available resources may be consumed more rapidly than currently anticipated, resulting in the need for additional funding.